110 related articles for article (PubMed ID: 24128680)
1. Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.
Wüthrich C; Popescu BF; Gheuens S; Marvi M; Ziman R; Denq SP; Tham M; Norton E; Parisi JE; Dang X; Lucchinetti CF; Koralnik IJ
J Neuropathol Exp Neurol; 2013 Nov; 72(11):1043-51. PubMed ID: 24128680
[TBL] [Abstract][Full Text] [Related]
2. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
Moser T; Zimmermann G; Baumgartner A; Berger T; Bsteh G; Di Pauli F; Enzinger C; Fertl E; Heller T; Koppi S; Rommer PS; Safoschnik G; Seifert-Held T; Stepansky R; Sellner J
J Neurol; 2024 Jan; 271(1):374-385. PubMed ID: 37728757
[TBL] [Abstract][Full Text] [Related]
4. Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis.
O'Leary S; Brugger HT; Wallentine D; Sershon L; Goff E; Saldana-King T; Beavin J; Avila RL; Rutledge D; Moore M
J Infus Nurs; 2023 Nov-Dec 01; 46(6):347-359. PubMed ID: 37920108
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration.
Dunham SR; Schmidt R; Clifford DB
Neurotherapeutics; 2020 Jul; 17(3):955-965. PubMed ID: 32166631
[TBL] [Abstract][Full Text] [Related]
6. Pathology for severe inflammatory PML with PD1/PD-L1 expression of favorable prognosis: What's a prognostic factor for PML-IRIS?
Shishido-Hara Y; Akimoto J; Fukami S; Kohno M; Matsubayashi J; Nagao T
Neuropathology; 2024 Feb; 44(1):47-58. PubMed ID: 37424276
[TBL] [Abstract][Full Text] [Related]
7. An autopsy case of progressive multifocal leukoencephalopathy with massive iron deposition in juxtacortical lesions.
Okamoto K; Takeda A; Hatsuta H; Sano T; Takao M; Ohsawa M; Miki Y; Nakamichi K; Itoh Y
Neuropathology; 2023 Oct; 43(5):396-402. PubMed ID: 36847459
[TBL] [Abstract][Full Text] [Related]
8. Successful epilepsy surgery in two cases with multiple sclerosis.
van Klink N; Tousseyn S; Schijns O; van Eijsden P; Vos P; Hilkman D; Killestein J; Leijten F
Epileptic Disord; 2023 Dec; 25(6):890-894. PubMed ID: 37792470
[TBL] [Abstract][Full Text] [Related]
9. Spinal cord involvement in progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome.
Moussaoui NE; Lambert N; Moussaoui ME; Bianchi E; Léonard P; Moïse M; Maquet P
J Neurovirol; 2024 May; ():. PubMed ID: 38778006
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of Progressive Multifocal Leukoencephalopathy Associated With Sarcoidosis Without Therapeutic Immune Suppression.
McEntire CRS; Fletcher A; Toledano M; Epstein S; White E; Tan CS; Mao-Draayer Y; Banks SA; Aksamit AJ; Gelfand JM; Thakur KT; Anand P; Cortese I; Bhattacharyya S
JAMA Neurol; 2023 Jun; 80(6):624-633. PubMed ID: 37093609
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned after 20 years of real-world experience with natalizumab.
Khatri BO; Olapo T; Beals S; Lindman E; Perea T; Van Zealand P; Metzger RR
Mult Scler Relat Disord; 2023 Dec; 80():105048. PubMed ID: 37866023
[TBL] [Abstract][Full Text] [Related]
12. Ring-Enhancing Progressive Multifocal Leukoencephalopathy Mimicking Glioma in a Presumed Immunocompetent Patient With a History of Multiple Sclerosis: A Case Report and Review of the Literature.
Gonzalez SC; Nguyen A; Soto JM; Shan Y
Cureus; 2023 Sep; 15(9):e45543. PubMed ID: 37868479
[TBL] [Abstract][Full Text] [Related]
13. An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations.
Kornek B
Patient Prefer Adherence; 2015; 9():675-84. PubMed ID: 26056435
[TBL] [Abstract][Full Text] [Related]
14. Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice.
Carruthers RL; Berger J
Mult Scler Relat Disord; 2014 Jul; 3(4):419-30. PubMed ID: 25877052
[TBL] [Abstract][Full Text] [Related]
15. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
[TBL] [Abstract][Full Text] [Related]
16. Mirtazapine and mefloquine therapy for non-AIDS-related progressive multifocal leukoencephalopathy.
Epperla N; Medina-Flores R; Mazza JJ; Yale SH
WMJ; 2014 Dec; 113(6):242-5. PubMed ID: 25745699
[TBL] [Abstract][Full Text] [Related]
17. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
[TBL] [Abstract][Full Text] [Related]
18. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
19. JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.
Agnihotri SP; Dang X; Carter JL; Fife TD; Bord E; Batson S; Koralnik IJ
Neurology; 2014 Aug; 83(8):727-32. PubMed ID: 25037207
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]